Patel Rajiv M, Walters Laura L, Kappes Ferdinand, Mehra Rohit, Fullen Douglas R, Markovitz David M, Ma Linglei
Department of Pathology, University of Michigan Medical Center, Ann Arbor, MI, USA.
J Cutan Pathol. 2012 Aug;39(8):753-7. doi: 10.1111/j.1600-0560.2012.01941.x. Epub 2012 Jul 5.
The chromatin architectural factor DEK maps to chromosome 6p and is frequently overexpressed in several neoplasms, including small cell lung carcinoma, where it is associated with poor prognosis, tumor initiation activity and chemoresistance. DEK expression has not been studied in cutaneous Merkel cell carcinoma.
We applied a DEK monoclonal antibody to 15 cases of Merkel cell carcinoma and 12 cases of small cell carcinoma. DEK nuclear immunoreactivity was scored based on percentage (0, negative; 1+, <25%; 2+, 25-50%; 3+, >50%) and intensity (weak, moderate or strong).
All 15 Merkel cell carcinoma cases (100%) showed diffuse (3+) nuclear positivity (14 strong, 1 weak). Six of 12 small cell carcinoma cases (50%) showed diffuse (3+) and strong nuclear positivity, while one case exhibited focal (1+) weak nuclear positivity. The remaining five cases were negative for DEK expression.
Our results suggest that DEK may be involved in the pathogenesis of Merkel cell carcinoma and therefore may provide therapeutic implications for Merkel cell carcinomas. In addition, the difference in DEK expression between Merkel cell carcinoma and small cell carcinoma suggests possible separate tumorigenesis pathways for the two tumors.
染色质结构因子DEK定位于6号染色体短臂,在包括小细胞肺癌在内的多种肿瘤中经常过度表达,在小细胞肺癌中它与预后不良、肿瘤起始活性和化疗耐药相关。尚未对皮肤默克尔细胞癌中的DEK表达进行研究。
我们将一种DEK单克隆抗体应用于15例默克尔细胞癌和12例小细胞癌。根据百分比(0,阴性;1+,<25%;2+,25 - 50%;3+,>50%)和强度(弱、中或强)对DEK核免疫反应性进行评分。
所有15例默克尔细胞癌病例(100%)均显示弥漫性(3+)核阳性(14例强阳性,1例弱阳性)。12例小细胞癌病例中有6例(50%)显示弥漫性(3+)强核阳性,而1例表现为局灶性(1+)弱核阳性。其余5例DEK表达为阴性。
我们的结果表明,DEK可能参与默克尔细胞癌的发病机制,因此可能为默克尔细胞癌提供治疗启示。此外,默克尔细胞癌和小细胞癌之间DEK表达的差异表明这两种肿瘤可能有不同的肿瘤发生途径。